ACP-103, a 5-HT2A receptor inverse agonist, as an adjunctive therapy in schizophrenia

被引：0
|
作者：
Vanover, Kimberly E.
机构：
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2006年 / 101卷
关键词：
5-HT2A; preclinical; clinical; schizophrenia;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [1] ACP-103, a potent 5-HT2A receptor inverse agonist, as an adjunctive therapy in schizophrenia
    Vanover, Kimberly E.
    Lameh, Jelveh
    Gardell, Luis R.
    Ott, Thomas R.
    Ma, Jian-Nong
    Burstein, Ethan S.
    van Kammen, Daniel
    Davis, Robert E.
    Weiner, David M.
    Brann, Mark R.
    [J]. ACTA PHARMACOLOGICA SINICA, 2006, 27 : 80 - 80
  • [2] Drug evaluation:: ACP-103, a 5-HT2A receptor inverse agonist
    Roberts, Claire
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (07) : 653 - 660
  • [3] PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain
    Nordstrom, Anna-Lena
    Mansson, Mattias
    Jovanovic, Hristina
    Karlsson, Per
    Halldin, Christer
    Farde, Lars
    Vanover, Kimberly E.
    Hacksell, Uli
    Brann, Mark R.
    Davis, Robert E.
    Weiner, David M.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 (02): : 163 - 171
  • [4] ACP-103, a 5-HT2A receptor inverse agonist, a novel potential treatment for psychosis
    Vanover, KE
    Weiner, DM
    Harvey, SC
    Powell, SB
    Geyer, MA
    Andersson, CM
    Tolf, BR
    Hacksell, U
    Brann, MR
    Davis, RE
    [J]. SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 317 - 317
  • [5] The tolerability of ACP-103, a 5-HT2A receptor inverse agonist in Parkinson's disease patients
    Weiner, DM
    Vanover, KE
    Hacksell, U
    Brann, MR
    Davis, RE
    [J]. MOVEMENT DISORDERS, 2005, 20 : S72 - S72
  • [6] ACP-103, a 5-HT2A receptor inverse agonist: Safety, tolerability, and pharmacokinetics in healthy volunteers
    Vanover, KE
    Weiner, DM
    Schlienger, N
    Thygesen, M
    Tolf, B
    Hacksell, U
    Brann, MR
    Davis, RE
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S253 - S253
  • [7] ACP-103 -: 5-HT2A receptor inverse agonist -: Treatment of psychosis -: Treatment of sleep disorders
    Wang, Y.
    Bolos, J.
    Serradell, N.
    [J]. DRUGS OF THE FUTURE, 2006, 31 (11) : 939 - 943
  • [8] ACP-103, a novel 5-HT2A receptor inverse agonist, improves the efficacy and side effect profile of haloperidol in experimental models
    Gardell, LR
    Barido, RL
    Pounds, L
    Johnson, RW
    Anderson, GT
    Veinbergs, I
    Bonhaus, DW
    Hacksell, U
    Brann, MR
    Davis, RE
    Vanover, KE
    [J]. SCHIZOPHRENIA RESEARCH, 2006, 81 : 49 - 49
  • [9] A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model
    Vanover, Kimberly E.
    Betz, Adrienne J.
    Weber, Suzanne M.
    Bibbiani, Francesco
    Kielaite, Aiste
    Weiner, David M.
    Davis, Robert E.
    Chase, Thomas N.
    Salamone, John D.
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2008, 90 (04) : 540 - 544
  • [10] 5-HT2A receptor occupancy and pharmacodynamic measures at plasma steady state with ACP-103
    Vanover, K.
    Weiner, D.
    Davis, R.
    van Kammen, D.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S251 - S252
12345